Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06956196
PHASE3

Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

Sponsor: Keymed Biosciences Co.Ltd

View on ClinicalTrials.gov

Summary

This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, Pharmacokinetics(PK), PharmacoDynamics(PD) and immunogenicity of Stapokibatrt in children with moderate-to-severe atopic dermatitis.

Official title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Stapokibatrt in Children With Moderate-to-severe Atopic Dermatitis

Key Details

Gender

All

Age Range

2 Years - 11 Years

Study Type

INTERVENTIONAL

Enrollment

240

Start Date

2025-05

Completion Date

2026-08

Last Updated

2025-05-04

Healthy Volunteers

No

Interventions

BIOLOGICAL

Stapokibatrt

Stapokibatrt 1 or 2 ml,Subcutaneous injection(SC)

OTHER

Placebo

Placebo of matching volume,Subcutaneous injection(SC)

Locations (1)

Beijing Children's Hospital Capital Medical University

Beijing, China